Case Studies, Pharmaceutical

Case Study – Bidose Nasal Spray Pump for Depression

Treatment resistant depression (TRD) affects 1 in 3 sufferers of depression creating an urgent need for therapeutics that differ in action to conventional anti-depressants. This case study describes a collaborative project to develop an esketamine nasal spray to meet this demand. The developed product utilizes Aptar Pharma’s patented Bidose nasal spray pump to deliver two subsequent drug doses, providing patients with a non-invasive, self-administered option for treatment. Use is heavily regulated due to the addictive nature of esketamine but the product has delivered promising results when used in combination with oral anti-depressants. Formulation as a nasal spray exploits recognized potential for ‘nose to brain’ drug delivery and has proven effective in minimizing side effects. The product is a first-in-class solution for TRD and was recognized as one of the top new drugs of 2019 with respect to sales potential.

Download Case Study - Bidose Nasal Spray Pump for Depression
8 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

8 Sep 2022

Case Study – Bidose Nasal Spray Pump for Depression

Case Studies, Pharmaceutical, Product Solutions, Device Innovations, Market Insights

Read More
8 Sep 2022

Case Study – Unidose Nasal Spray Pump in Hypoglycemia

Case Studies, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
8 Sep 2022

Case Study – Unidose Nasal Spray Pump for Opioid Overdose

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 Sep 2022

Spray Dried Formulations for Nasal Applications – Challenges an...

Publications, Pharmaceutical, Device Innovations, Product Solutions

Read More
1 2 3 16

Request Access

Close

Requesting access to Case Study – Bidose Nasal Spray Pump for Depression.

  • This field is for validation purposes and should be left unchanged.
Back To Top